SCHEMBL21828343

SCHEMBL21828343

CCCCCCCCOC(CCCCCCNCCO)OCCCCCCCC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
TP53 P04637 2/20 0.42
TSHR P16473 1/20 0.42
ALOX15 P16050 1/20 0.42
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 1/20 0.39
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.38
SMPD1 P17405 3/20 0.38
S1PR2 O95136 3/20 0.38
S1PR4 O95977 3/20 0.38
S1PR1 P21453 3/20 0.38
S1PR3 Q99500 3/20 0.38
S1PR5 Q9H228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21828359 1.00 ALDH1A1 (0.42) ALDH1A1TP53TSHRALOX15KDM4E
SCHEMBL26731555 1.00 ALDH1A1 (0.42) ALDH1A1TP53TSHRALOX15KDM4E
SCHEMBL25644246 0.85 TSHR (0.45) ALDH1A1TSHRMEN1KMT2ASMPD1
SCHEMBL24588895 0.83 NAAA (0.43) TP53ALOX15
SCHEMBL29774929 0.83 NAAA (0.43) TP53ALOX15
SCHEMBL24573296 0.83 LPAR2 (0.39) ALDH1A1TP53ALOX15KDM4ELMNA
SCHEMBL31578697 0.83 LMNA (0.52) ALDH1A1TSHRLMNAHSD17B10MEN1
SCHEMBL31647994 0.83 LMNA (0.52) ALDH1A1TSHRLMNAHSD17B10MEN1
SCHEMBL31252980 0.81 LMNA (0.48) ALDH1A1TSHRLMNAHSD17B10MEN1
SCHEMBL16013242 0.81 LMNA (0.48) ALDH1A1TSHRLMNAHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113039174-B Ionizable amine lipids 英特利亚治疗股份有限公司 2023-11-17 CN disclosed
US-20220009878-A1 IONIZABLE AMINE LIPIDS INTELLIA THERAPEUTICS, INC. 2022-01-13 US disclosed
WO-2021222287-A2 METHODS OF IN VITRO CELL DELIVERY INTELLIA THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
EP-3860972-A1 IONIZABLE AMINE LIPIDS Intellia Therapeutics, Inc. (US) 2021-08-11 EP disclosed
CN-113039174-A Ionizable amine lipids 英特利亚治疗股份有限公司 2021-06-25 CN disclosed
WO-2020072605-A1 IONIZABLE AMINE LIPIDS INTELLIA THERAPEUTICS, INC. (US) 2020-04-09 WO disclosed
WO-2020072605-A1 IONIZABLE AMINE LIPIDS INTELLIA THERAPEUTICS, INC. (US) 2020-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009878-A1 IONIZABLE AMINE LIPIDS PHOSPHO1, SGMS1, SGMS2 ALDH1A1 2334/4885TP53 1352/4885TSHR 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.